Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

医学 阿替唑单抗 肿瘤科 卡铂 内科学 化疗 肺癌 成本效益 癌症 成本效益分析 顺铂 免疫疗法 彭布罗利珠单抗 风险分析(工程)
作者
Dong Ding,Huabin Hu,Mengting Liao,Yin Shi,Longjiang She,Linli Yao,Youwen Zhu,Shan Zeng,Jin Huang
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
卷期号:37 (5): 2116-2126 被引量:27
标识
DOI:10.1007/s12325-020-01292-3
摘要

The purpose of this study was to estimate the cost-effectiveness of atezolizumab plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the United States (US) payers’ perspective in the first-line treatment. A mathematical Markov model was developed to estimate cost and effectiveness of atezolizumab combination therapy versus carboplatin plus nab-paclitaxel alone in the first-line therapy of metastatic non-squamous NSCLC from the data of IMpower130. Costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were analyzed, and model robustness was assessed by sensitivity analysis. Additional subgroup analyses were performed as well. Compared to chemotherapy, treatment with atezolizumab plus chemotherapy yields an increase of 0.16 QALYs with an increase in cost of $109,809.13, resulting in an ICER of $670,309.66 per QALY. The most influential factor in this model was the cost of atezolizumab. Probabilistic sensitivity analysis showed that there was 0% probability that atezolizumab plus chemotherapy was cost-effective at willingness-to-pay (WTP) values of $150,000 per QALY. The results of subgroup analyses showed that the ICER remained greater than $150,000/QALY across the all patient subgroups. First-line treatment with atezolizumab in combination with carboplatin plus nab-paclitaxel is not a cost-effective option in patients with metastatic non-squamous NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
独特乘云发布了新的文献求助10
刚刚
WELXCNK发布了新的文献求助10
刚刚
setuin发布了新的文献求助10
1秒前
烟花应助aixue采纳,获得10
2秒前
CC完成签到,获得积分10
2秒前
tyh完成签到,获得积分10
2秒前
完美世界应助Huang采纳,获得10
3秒前
大李完成签到,获得积分10
3秒前
4秒前
4秒前
5秒前
乐乐乐乐乐乐应助大橙子采纳,获得10
5秒前
ylw发布了新的文献求助10
5秒前
独特乘云完成签到,获得积分10
6秒前
暮雨发布了新的文献求助10
6秒前
情怀应助zhaopeipei采纳,获得10
6秒前
6秒前
嘿嘿完成签到,获得积分20
7秒前
量子星尘发布了新的文献求助10
7秒前
7秒前
李健应助zhuxiaonian采纳,获得10
7秒前
星辰大海应助setuin采纳,获得10
7秒前
1335804518完成签到 ,获得积分10
8秒前
9秒前
10秒前
Seyn发布了新的文献求助10
11秒前
SciGPT应助ylw采纳,获得10
11秒前
典雅牛青发布了新的文献求助10
11秒前
12秒前
12秒前
科研通AI5应助lh961129采纳,获得10
12秒前
WJH发布了新的文献求助10
13秒前
14秒前
16秒前
16秒前
科研小虫完成签到,获得积分10
17秒前
等待安柏发布了新的文献求助10
18秒前
Xinxxx发布了新的文献求助10
18秒前
18秒前
18秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038657
求助须知:如何正确求助?哪些是违规求助? 3576306
关于积分的说明 11375198
捐赠科研通 3306108
什么是DOI,文献DOI怎么找? 1819379
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066